Kolon Life Science Inc (102940) - Total Assets
Based on the latest financial reports, Kolon Life Science Inc (102940) holds total assets worth ₩642.14 Billion KRW (≈ $435.17 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 102940 book value for net asset value and shareholders' equity analysis.
Kolon Life Science Inc - Total Assets Trend (2014–2024)
This chart illustrates how Kolon Life Science Inc's total assets have evolved over time, based on quarterly financial data.
Kolon Life Science Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Kolon Life Science Inc's total assets of ₩642.14 Billion consist of 24.3% current assets and 75.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩12.42 Billion | 3.0% |
| Accounts Receivable | ₩36.82 Billion | 8.8% |
| Inventory | ₩46.73 Billion | 11.1% |
| Property, Plant & Equipment | ₩115.08 Billion | 27.4% |
| Intangible Assets | ₩599.20 Million | 0.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Kolon Life Science Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Kolon Life Science Inc (102940) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kolon Life Science Inc's current assets represent 24.3% of total assets in 2024, a decrease from 33.0% in 2014.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2024, up from 2.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 27.4% of total assets.
Kolon Life Science Inc Competitors by Total Assets
Key competitors of Kolon Life Science Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Theragen Etex Co.Ltd
KQ:066700
|
Korea | ₩245.25 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
Kolon Life Science Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.56 | 0.51 | 0.69 |
| Quick Ratio | 0.27 | 0.25 | 0.40 |
| Cash Ratio | 0.00 | 0.07 | 0.00 |
| Working Capital | ₩-81.27 Billion | ₩-91.86 Billion | ₩-44.59 Billion |
Kolon Life Science Inc - Advanced Valuation Insights
This section examines the relationship between Kolon Life Science Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 35.6% |
| Total Assets | ₩419.56 Billion |
| Market Capitalization | $453.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kolon Life Science Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Kolon Life Science Inc's assets grew by 35.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kolon Life Science Inc (2014–2024)
The table below shows the annual total assets of Kolon Life Science Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩419.56 Billion ≈ $284.33 Million |
+35.59% |
| 2023-12-31 | ₩309.44 Billion ≈ $209.70 Million |
-1.49% |
| 2022-12-31 | ₩314.12 Billion ≈ $212.87 Million |
+33.86% |
| 2021-12-31 | ₩234.66 Billion ≈ $159.02 Million |
-5.51% |
| 2020-12-31 | ₩248.34 Billion ≈ $168.29 Million |
-10.76% |
| 2019-12-31 | ₩278.29 Billion ≈ $188.60 Million |
-55.03% |
| 2018-12-31 | ₩618.90 Billion ≈ $419.42 Million |
-13.66% |
| 2017-12-31 | ₩716.80 Billion ≈ $485.76 Million |
+102.16% |
| 2016-12-31 | ₩354.57 Billion ≈ $240.29 Million |
+55.10% |
| 2015-12-31 | ₩228.62 Billion ≈ $154.93 Million |
+9.44% |
| 2014-12-31 | ₩208.90 Billion ≈ $141.57 Million |
-- |
About Kolon Life Science Inc
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more